{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17","value":"39"},{"groupId":"OG001","spread":"8","value":"30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11","value":"27"},{"groupId":"OG001","spread":"12","value":"25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"4 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15","value":"28"},{"groupId":"OG001","spread":"7","value":"22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"8 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. Patient-reported assessment of neuropathy based on 19 questions from components of sensory, motor, and autonomic neuropathic. Question responses are (scale of 1 to 4) 1 being \"not at all\" and 4 being \"very much.\" The total EORTC score (calculated as the average of the component responses) (range 1-4) and then converted to a 100 point scale (range 0-100) with higher scores having more severe symptoms or greater functional limitation. EORTC QLQ-CIPN20 (PRO) will be done at baseline, and at 4 and 8 weeks of cryocompression therapy.","dispersionType":"Standard Deviation","groups":[{"description":"VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG000","title":"Grade 2-3 Established Neuropathy"},{"description":"VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG001","title":"Grade 1-2 New-onset Neuropathy"}],"paramType":"MEAN","populationDescription":"18 completed baseline, 14 completed 4 week assessment, 16 completed 8 week assessment. Decreased sample sizes at 4 and 8 weeks is due to patient withdrawal and patient refusals.","reportingStatus":"POSTED","timeFrame":"Baseline, 4 weeks, 8 weeks","title":"EORTC QLQ-CIPN20 Questionnaire","type":"SECONDARY","unitOfMeasure":"score on a scale"}